MASCC/ISOO Clinical Practice Statement: Management of salivary gland hypofunction and xerostomia in cancer patients

Catherine Hong; Siri Beier Jensen; Arjan Vissink; Pierluigi Bonomo; Alan Roger Santos-Silva; Luiz Alcino Gueiros; Joel B. Epstein; Sharon Elad

doi:10.1007/s00520-024-08688-9

MASCC/ISOO Clinical Practice Statement: Management of salivary gland hypofunction and xerostomia in cancer patients

Catherine Hong^*, Siri Beier Jensen, Arjan Vissink, Pierluigi Bonomo, Alan Roger Santos-Silva, Luiz Alcino Gueiros, Joel B. Epstein, Sharon Elad

^*Corresponding author for this work

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

2 Citations (Scopus)

Abstract

Purpose: A MASCC/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise tool for clinicians that concentrates practical information needed for the management of oral complications of cancer patients. This CPS is focused on the management of salivary gland hypofunction and xerostomia in cancer patients. Methods: This CPS was developed based on critical evaluation of the literature followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group of MASCC/ISOO. The information is presented in the form of succinct bullets and tables to generate a short manual about the best standard of care. Results: Salivary gland hypofunction and xerostomia in cancer patients are managed by (i) stimulating saliva production of salivary glands with residual secretory capacity or (ii) artificial wetting of the oral and lip surfaces which can be achieved by pharmacological or non-pharmacological interventions. Pharmacological interventions encompass the use of sialagogues and sialolytics, while non-pharmacological interventions involve the use of moistening agents, mechanical, gustatory, or electrostimulation of the salivary glands. Additional treatment modalities may be incorporated in practice based on local availability and the clinician’s experience. Conclusion: The information presented in this CPS offers clinicians convenient access to the dosages and regimens of different interventions for managing salivary gland hypofunction or xerostomia to facilitate clinical efficiency and conserve valuable time for clinicians.

Original language	English
Article number	548
Journal	Supportive Care in Cancer
Volume	32
Issue	8
ISSN	0941-4355
DOIs	https://doi.org/10.1007/s00520-024-08688-9
Publication status	Published - Aug 2024

Keywords

Cancer
Dry mouth
Oral manifestations
Salivary gland hypofunction
Xerostomia

Access to Document

10.1007/s00520-024-08688-9

Cite this

@article{4575c5e33a3c43cbb23c835b78492e7f,

title = "MASCC/ISOO Clinical Practice Statement: Management of salivary gland hypofunction and xerostomia in cancer patients",

abstract = "Purpose: A MASCC/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise tool for clinicians that concentrates practical information needed for the management of oral complications of cancer patients. This CPS is focused on the management of salivary gland hypofunction and xerostomia in cancer patients. Methods: This CPS was developed based on critical evaluation of the literature followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group of MASCC/ISOO. The information is presented in the form of succinct bullets and tables to generate a short manual about the best standard of care. Results: Salivary gland hypofunction and xerostomia in cancer patients are managed by (i) stimulating saliva production of salivary glands with residual secretory capacity or (ii) artificial wetting of the oral and lip surfaces which can be achieved by pharmacological or non-pharmacological interventions. Pharmacological interventions encompass the use of sialagogues and sialolytics, while non-pharmacological interventions involve the use of moistening agents, mechanical, gustatory, or electrostimulation of the salivary glands. Additional treatment modalities may be incorporated in practice based on local availability and the clinician{\textquoteright}s experience. Conclusion: The information presented in this CPS offers clinicians convenient access to the dosages and regimens of different interventions for managing salivary gland hypofunction or xerostomia to facilitate clinical efficiency and conserve valuable time for clinicians.",

keywords = "Cancer, Dry mouth, Oral manifestations, Salivary gland hypofunction, Xerostomia",

author = "Catherine Hong and Jensen, {Siri Beier} and Arjan Vissink and Pierluigi Bonomo and Santos-Silva, {Alan Roger} and Gueiros, {Luiz Alcino} and Epstein, {Joel B.} and Sharon Elad",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.",

year = "2024",

month = aug,

doi = "10.1007/s00520-024-08688-9",

language = "English",

volume = "32",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer",

number = "8",

}

MASCC/ISOO Clinical Practice Statement: Management of salivary gland hypofunction and xerostomia in cancer patients. / Hong, Catherine; Jensen, Siri Beier; Vissink, Arjan et al.
In: Supportive Care in Cancer, Vol. 32, No. 8, 548, 08.2024.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

TY - JOUR

T1 - MASCC/ISOO Clinical Practice Statement

T2 - Management of salivary gland hypofunction and xerostomia in cancer patients

AU - Hong, Catherine

AU - Jensen, Siri Beier

AU - Vissink, Arjan

AU - Bonomo, Pierluigi

AU - Santos-Silva, Alan Roger

AU - Gueiros, Luiz Alcino

AU - Epstein, Joel B.

AU - Elad, Sharon

N1 - Publisher Copyright: © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.

PY - 2024/8

Y1 - 2024/8

N2 - Purpose: A MASCC/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise tool for clinicians that concentrates practical information needed for the management of oral complications of cancer patients. This CPS is focused on the management of salivary gland hypofunction and xerostomia in cancer patients. Methods: This CPS was developed based on critical evaluation of the literature followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group of MASCC/ISOO. The information is presented in the form of succinct bullets and tables to generate a short manual about the best standard of care. Results: Salivary gland hypofunction and xerostomia in cancer patients are managed by (i) stimulating saliva production of salivary glands with residual secretory capacity or (ii) artificial wetting of the oral and lip surfaces which can be achieved by pharmacological or non-pharmacological interventions. Pharmacological interventions encompass the use of sialagogues and sialolytics, while non-pharmacological interventions involve the use of moistening agents, mechanical, gustatory, or electrostimulation of the salivary glands. Additional treatment modalities may be incorporated in practice based on local availability and the clinician’s experience. Conclusion: The information presented in this CPS offers clinicians convenient access to the dosages and regimens of different interventions for managing salivary gland hypofunction or xerostomia to facilitate clinical efficiency and conserve valuable time for clinicians.

AB - Purpose: A MASCC/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise tool for clinicians that concentrates practical information needed for the management of oral complications of cancer patients. This CPS is focused on the management of salivary gland hypofunction and xerostomia in cancer patients. Methods: This CPS was developed based on critical evaluation of the literature followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group of MASCC/ISOO. The information is presented in the form of succinct bullets and tables to generate a short manual about the best standard of care. Results: Salivary gland hypofunction and xerostomia in cancer patients are managed by (i) stimulating saliva production of salivary glands with residual secretory capacity or (ii) artificial wetting of the oral and lip surfaces which can be achieved by pharmacological or non-pharmacological interventions. Pharmacological interventions encompass the use of sialagogues and sialolytics, while non-pharmacological interventions involve the use of moistening agents, mechanical, gustatory, or electrostimulation of the salivary glands. Additional treatment modalities may be incorporated in practice based on local availability and the clinician’s experience. Conclusion: The information presented in this CPS offers clinicians convenient access to the dosages and regimens of different interventions for managing salivary gland hypofunction or xerostomia to facilitate clinical efficiency and conserve valuable time for clinicians.

KW - Cancer

KW - Dry mouth

KW - Oral manifestations

KW - Salivary gland hypofunction

KW - Xerostomia

UR - http://www.scopus.com/inward/record.url?scp=85199437951&partnerID=8YFLogxK

U2 - 10.1007/s00520-024-08688-9

DO - 10.1007/s00520-024-08688-9

M3 - Review

C2 - 39048728

AN - SCOPUS:85199437951

SN - 0941-4355

VL - 32

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 8

M1 - 548

ER -

MASCC/ISOO Clinical Practice Statement: Management of salivary gland hypofunction and xerostomia in cancer patients

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this